Monetary Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Monetary Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$252K	Buy	565 +10	+2%	+$4.66K	0.06%	188
2025 Q4	$252K	Hold	555	–	–	0.06%	184
2025 Q3	$217K	Hold	555	–	–	0.05%	193
2025 Q2	$247K	Hold	555	–	–	0.06%	188
2025 Q1	$269K	Sell	555 -50	-8%	-$23.3K	0.07%	176
2024 Q4	$244K	Sell	605 -565	-48%	-$262K	0.06%	186
2024 Q3	$544K	Sell	1,170 -50	-4%	-$24K	0.14%	138
2024 Q2	$572K	Buy	1,220 +100	+9%	+$43.4K	0.15%	129
2024 Q1	$468K	Buy	+1,120	New	+$473K	0.13%	139
2021 Q3	–	Sell	-300	Closed	-$60K	–	352
2021 Q2	$60K	Hold	300	–	–	0.02%	240
2021 Q1	$64K	Sell	300 -150	-33%	-$32.9K	0.02%	227
2020 Q4	$106K	Hold	450	–	–	0.03%	198
2020 Q3	$122K	Hold	450	–	–	0.04%	182
2020 Q2	$131K	Hold	450	–	–	0.05%	170
2020 Q1	$107K	Hold	450	–	–	0.05%	163
2019 Q4	$99K	Hold	450	–	–	0.04%	198
2019 Q3	$76K	Buy	+450	New	+$79.6K	0.03%	213
2015 Q3	–	Sell	-250	Closed	-$31K	–	344
2015 Q2	$31K	Sell	250 -600	-71%	-$75.6K	0.01%	280
2015 Q1	$100K	Buy	+850	New	+$102K	0.04%	203

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Monetary Management Group's VRTX Position: Q1 2026 in Review

Monetary Management Group increased its Vertex Pharmaceuticals (VRTX) stake by 1.8% in Q1 2026, buying an estimated $4.66K and bringing the position to 565 shares worth $252K. The position accounts for 0.06% of the portfolio, ranked #188.

Monetary Management Group first reported a position in VRTX in Q1 2015 and has held it in 19 quarters since. The position peaked at $572K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Monetary Management Group held 565 shares of Vertex Pharmaceuticals worth $252K as of Q1 2026.
Monetary Management Group bought 10 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.66K.
Vertex Pharmaceuticals made up 0.06% of Monetary Management Group's portfolio in Q1 2026, its #188 holding.
Monetary Management Group first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 19 quarters since.
Monetary Management Group's Vertex Pharmaceuticals position peaked at $572K in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Monetary Management Group's 13F filing for Q1 2026, filed 13 May 2026.